Kissei Pharmaceutical Co., Ltd.
OTC: KSPHF0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Other OTC
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- CEO
- Mutsuo Kanzawa
- Employees
- 1,778
- Headquarters
- Matsumoto, Japan
- IPO year
- 2017
- Market cap
- $1.1B
- Website
- https://www.kissei.co.jp
Loading KSPHF…
Loading profile data…Frequently asked questions about KSPHF
What does Kissei Pharmaceutical Co., Ltd. (KSPHF) do?
Kissei Pharmaceutical Co., Ltd. researches, develops, manufactures, and sells pharmaceutical products primarily in Japan. The company offers Calogra tablets, for the treatment of ulcerative colitis; Tabneos capsules for the treatment of microscopic polyangiitis and granulomatous polyangiitis; Minirin Melt OD tablets; Corsuba Intravenous Dialysis...
Where does KSPHF trade?
Kissei Pharmaceutical Co., Ltd. (KSPHF) trades on the Other OTC.
What sector is KSPHF in?
Kissei Pharmaceutical Co., Ltd. (KSPHF) operates in the Healthcare sector, specifically in the Medical - Pharmaceuticals industry.
Who is the CEO of Kissei Pharmaceutical Co., Ltd.?
Mutsuo Kanzawa is the chief executive officer of Kissei Pharmaceutical Co., Ltd. (KSPHF).
Where is Kissei Pharmaceutical Co., Ltd. headquartered?
Kissei Pharmaceutical Co., Ltd. is headquartered in Japan.
Does KSPHF pay a dividend?
Yes — Kissei Pharmaceutical Co., Ltd. (KSPHF) paid a trailing twelve-month dividend of USD 1.03 per share. Frequency and ex-dividend dates are tracked on the dividends tab.
When did KSPHF go public?
Kissei Pharmaceutical Co., Ltd. (KSPHF) completed its initial public offering in 2017.